IMPROVE SLEEP.
ONE BREATH AT A TIME®
IMPROVE LIFE.
ONE DAY AT A TIME™
IMPROVE SLEEP.
ONE BREATH AT A TIME®
IMPROVE LIFE.
ONE DAY AT A TIME™
central sleep apnea
Central Sleep Apnea (CSA) is a serious condition that results in shallow or disrupted breathing during sleep. Learn more about the causes, symptoms, and treatment options for CSA.
Central Sleep Apnea (CSA) is a serious condition that results in shallow or disrupted breathing during sleep. Learn more about the causes, symptoms, and treatment options for CSA.
The remedē® System is an implantable, non-mask therapy designed for adult patients with moderate to severe central sleep apnea.
The latest advancement in remedē System technology is now FDA approved.
WATCH A VIDEO
explaining central sleep apnea and the remedē System
clinicians
Learn about remedē, including study
results, peer-reviewed publications, and
patient identification.
Learn about remedē, including study results, peer-reviewed publications, and patient identification.
Founded in 2006 and headquartered in Minnesota, Respicardia is a leader in innovative technologies that address the unmet needs of people with Central Sleep Apnea (CSA). CSA results from the brain’s inability to send appropriate signals to the respiratory muscles to stimulate breathing during sleep. CSA is a serious breathing disorder that disrupts the normal breathing pattern and negatively affects quality of life and overall health.1
The remedē® System, which received U.S. Food and Drug Administration (FDA) approval in October 2017, is a breakthrough implantable system that treats the harmful effects of CSA by restoring a more normal breathing pattern during sleep.2
- Costanzo MR, Khayat R, Ponikowski P, et al. State-of-the-art review: Mechanisms and clinical consequences of untreated central sleep apnea in heart failure. J Am Coll Cardiol 2015;65:72-84.
- Costanzo M, et al. Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. The Lancet. 2016; 388: 974–82.
